BOSTON — As if being admitted to the hospital weren’t bad enough, patients, once admitted, are at higher risk of becoming infected with a “superbug” bacterium, Clostridium difficile (C. difficile). The toxins produced by C. difficile kill human intestinal cells by causing them to burst open, allowing the bacteria to use them as fuel. This results in severe diarrhea and, in rare cases, death. Abraham “Linc” Sonenshein, PhD, and colleagues from the Department of Molecular Biology and Microbiology at the Tufts University School of Medicine (TUSM) and the Sackler School of Graduate Biomedical Sciences at Tufts, have discovered how a protein called CodY regulates the genes that control production of the dangerous toxins. Understanding the relationship between CodY and C. difficile is an important step toward the development of a drug that may prevent hospital patients from falling ill.
Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4
/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;}
“The C. difficile bacteria only produce toxins when they are in need of food,” explains Sonenshein, professor of microbiology at TUSM and corresponding author on the paper to be published in Molecular Microbiology. “We found that the CodY protein, in essence, monitors the hunger level of C. difficile, preventing toxin production when the bacteria have enough to eat.” Sonenshein, along with first author Sean Dineen, PhD, and other Tufts colleagues developed a series of experiments to investigate the importance of CodY and how this protein communicates to bacteria that it is time to search for new sources of food.
The researchers first developed a mutant strain of C. difficile bacteria that does not make the protein CodY, and compared the amount of toxin produced by the mutant strain of bacteria to the amount of toxin produced by normal bacteria. The mutant strain produced much higher levels of toxin. The presence of CodY seems to tell the bacterial cells that they are well-fed and there is no reason to make toxin that kills intestinal cells for fuel. Lack of CodY activity, however, indicates to the bacteria that they are lacking key nutrients and that it is time to make the toxins they need to get food from the host cells.
To determine how CodY tells the bacteria not to make toxins, Sonenshein and colleagues removed DNA from the bacteria, and observed the interaction of the DNA and the CodY protein in vitro. They found that CodY targeted the region of the bacterial chromosome that includes the toxin genes. “When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin,” says Sonenshein. “Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells.”
Knowing what turns on, and more importantly, what turns off the toxin-producing genes in C. difficile opens the door for treatment and prevention options. “It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production.”
The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, US Public Health Service, Department of Health and Human Services.
Dineen SS, Villapakkam AC, Nordman JT, and Sonenshein AL. Molecular Microbiology. 2007. Early online edition; doi: 10.1111/j.1365-2958.2007.05906.x “Repression of Clostridium difficile toxin gene expression by CodY.”
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.
###
A note regarding the above references to the Sackler School: In December 2019, Tufts University announced that it would remove the Sackler name from all programs and facilities—including the Sackler School of Graduate Biomedical Sciences. At that time, the school was renamed the Graduate School of Biomedical Sciences.
